Lithia Motors, Inc. Common Stock (LAD) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor
NEWS SCORE
50/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
78
Good based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$331.37
Trend Context
Mixed / range
Latest briefing
What's happening with LAD
globenewswire.com14 Jul 2026
Lithia & Driveway (LAD) Schedules Release of Second Quarter 2026 Results
MEDFORD, Ore., July 14, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD) today announced its second quarter 2026 results will be released before the market opens on Wednesday, July 29, 2026. A conference call to discuss the earnings results is scheduled for the same day at 10:00 a.m. Eastern Time.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com9 Jun 2026
Lithia & Driveway (LAD) Rises to Number 123 on 2026 Fortune 500 List
MEDFORD, Ore., June 09, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD) today announced that it ranked No.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com3 Jun 2026
JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
